Eli Lilly and Company (LLY)
| Market Cap | 1.14T +47.6% |
| Revenue (ttm) | 79.67B +49.6% |
| Net Income | 26.71B +93.6% |
| EPS | 29.79 +94.8% |
| Shares Out | 891.36M |
| PE Ratio | 42.75 |
| Forward PE | 32.95 |
| Dividend | $6.92 (0.54%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 2,277,425 |
| Open | 1,304.15 |
| Previous Close | 1,306.69 |
| Day's Range | 1,257.62 - 1,307.92 |
| 52-Week Range | 806.02 - 1,321.21 |
| Beta | 0.45 |
| Analysts | Buy |
| Price Target | 1,331.55 (+4.56%) |
| Earnings Date | Oct 29, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 31 analysts, the average rating for LLY stock is "Buy." The 12-month stock price target is $1,331.55, which is an increase of 4.56% from the latest price.
News
Eli Lilly announces new first-line data on olomorasib at 2026 ESMO
Eli Lilly and Company (LLY) announced new first-line data on olomorasib at the 2026 European Society for Medical Oncology, ESMO, Congress in Madrid, Spain. Results shared in a poster presentation…
Eli Lilly announces new Phase 1 data on Sofe-M
Eli Lilly (LLY) and Company announced new Phase 1 data showing that its investigational folate receptor alpha antibody-drug conjugate sofetabart mipitecan, Sofe-M, plus bevacizumab achieved a confirme...
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FR α expression ...
Eli Lilly CEO previews the next generation of weight-loss drugs
Eli Lilly chair and CEO Dave Ricks discusses the company's expansion and 150th year in business on ‘Claman's Power Players.'
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
The combined China-India-Brazil market for weight-loss drugs could grow to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan estimated, as improving affordability and broader access drive...
Eli Lilly (LLY) Price Forecast: Breakout Strengthens Ahead of Earnings
Eli Lilly reaches a record high ahead of earnings, strengthening its bullish trend as technical signals point toward potential upside targets between $1,384 and $1,406.
Eli Lilly breaks ground on $5B manufacturing facility in Virginia
Eli Lilly (LLY) and Company broke ground on a new $5B manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since…
Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
First Lilly site to produce both active pharmaceutical ingredients and finished medicines in a fully integrated facility Site will create 650 high-wage jobs INDIANAPOLIS, Oct. 22, 2026 /PRNewswire/ --...
Eli Lilly price target raised to $1,316 from $1,309 at Leerink
Leerink raised the firm’s price target on Eli Lilly (LLY) to $1,316 from $1,309 and keeps an Outperform rating on the shares. The firm’s investment thesis is that it expects…
Eli Lilly Stock (LLY) Hits All-Time High Ahead of Earnings
The pharma giant reports financial results on Oct. 29.
Eli Lilly price target raised to $1,413 from $1,371 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Eli Lilly (LLY) to $1,413 from $1,371 and keeps a Buy rating on the shares. Eli Lilly is expected to deliver another…
METiS TechBio enters up to $1.1B collaboration with Eli Lilly
METiS TechBio announced a strategic collaboration with Eli Lilly (LLY) and Company focused on the research and discovery of novel lipid nanoparticle-based delivery solutions designed to enable tissue-...
Eli Lilly price target raised to $1,397 from $1,341 at BofA
BofA raised the firm’s price target on Eli Lilly (LLY) to $1,397 from $1,341 and keeps a Buy rating on the shares. The firm’s Q3 physician obesity survey adds validation…
Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech
Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies...
Eli Lilly announces SHINE-2 study of Omvoh meets primary endpoint
Eli Lilly (LLY) announced late-breaking one-year results from the Phase 3 SHINE-2 study of Omvoh in pediatric patients ages 6 to 17 with moderately to severely active ulcerative colitis, or…
Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis
Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric ulcerative colitis More than...
Eli Lilly presents new data from its oncology portfolio at ESMO
Eli Lilly (LLY) and Company announced that new data from across its oncology portfolio will be presented at the European Society for Medical Oncology, ESMO, Congress, taking place October 23-27…
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
First Phase 1 data for sofetabart mipitecan, Lilly's investigational FR α -targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentation Updated first-line data for o...
EMA adopts positive opinion on Eli Lilly’s Foundayo, recommending approval
On October 15, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Foundayo, intended for th...
Lilly confirms date and conference call for third-quarter 2026 financial results announcement
INDIANAPOLIS, Oct. 15, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2026 financial results on October 29, 2026. Lilly will also conduct a conference call that...
Eli Lilly’s Omvoh shows efficacy in ulcerative colitis and Crohn’s disease
Eli Lilly (LLY) reported new data analyses showing patients with moderately to severely active ulcerative colitis, or UC, and Crohn’s disease treated with Omvoh achieved multiple treatment goals simul...
New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endosco...
Adlai Nortye enters CTCSAs with Eli Lilly, Merck KGaA for cetuximab
Adlai Nortye (ANL) announced clinical trial collaboration and supply agreements, or CTCSAs, with Eli Lilly (LLY) and Merck KGaA (MKGAF) for the anti-EGFR antibody cetuximab. These agreements will supp...